Are Surgeons Ready to Get the COVID-19 Vaccine?

NCT ID: NCT04799652

Last Updated: 2022-07-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

138 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-15

Study Completion Date

2021-08-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The COVID-19 pandemic continues to rage and most of the world is facing a second wave with continuous lockdown and strict measures aiming to control it. While vaccination is on its way, and has even started in several countries, trust and acceptance remain a challenge for an effective vaccination strategy, especially with the increasing vaccination hesitance in recent years . It is important to understand the main concerns towards the COVID-19 vaccine so they can be addressed in a constructive way - more specifically among health care professionals who are at the frontline of the pandemic.

The aim of this study is to evaluate whether surgeons are ready for the COVID-19 vaccine and to understand their main concerns towards the vaccine.

In an objective to evaluate the attitude of doctors towards the COVID vaccine and the effect of prolonged lockdown on their psychological burden, the investigators created an anonymous survey of 21 questions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Doctors within Belgian Hospitals

Survey

Intervention Type OTHER

Survey of 21 questions. The questions were divided into sections, evaluating demographics, COVID-19 test status and symptoms, the surgeon's opinion on the COVID-19 vaccination and their main concerns. The questionnaire was completed anonymously between 15/01/2021 and 24/01/2021, before the start of vaccination of health care professionals in a Belgian hospital.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Survey

Survey of 21 questions. The questions were divided into sections, evaluating demographics, COVID-19 test status and symptoms, the surgeon's opinion on the COVID-19 vaccination and their main concerns. The questionnaire was completed anonymously between 15/01/2021 and 24/01/2021, before the start of vaccination of health care professionals in a Belgian hospital.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Physicians affiliated to Belgian Hospitals

Exclusion Criteria

* None
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Brugmann University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pierre Wauthy

Medical Director of the CHU Brugmann

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yasser Farid

Role: PRINCIPAL_INVESTIGATOR

CHU Brugmann

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Brugmann

Brussels, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHUB-Farid-vaccination

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.